Recent News
- Radius Appoints Ed Cinca as Chief Commercial Officer
- Radius’ Abaloparatide Receives Positive CHMP Opinion for the Treatment of Osteoporosis in Postmenopausal Women at Increased Risk of Fracture
- Radius Announces Publication of Abaloparatide Phase 3 ATOM Trial Data in the Journal of Bone and Mineral Research
- Radius Appoints Scott Briggs as Chief Executive Officer
- Teijin Pharma Receives Additional Approval in Japan for Abaloparatide Acetate as Treatment for Osteoporosis
- Menarini Group’s Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA) for the Treatment of ER+/HER2- Advanced or Metastatic Breast Cancer
- Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc.
- Radius Health Announces Agreement to be Acquired by Gurnet Point Capital and Patient Square Capital